Unique Plan Description: Baricitinib EUA COVID19
Plan Selection Display: Baricitinib EUA COVID19
PlanType: Medical                                 
Version: 1          
Begin Effective Date: 2021-12-02 11:21:00
End Effective Date: 2100-12-31 00:00:00
Last Updated Date: 2021-12-20 09:30:46
Available at all facilities: Yes

Baricitinib EUA COVID19
Medications
		<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><HTML><HEAD><META content="text/html; charset=windows-1252" http-equiv=Content-Type><STYLE> BODY margin:0; P margin:0 </STYLE><META name=GENERATOR content="MSHTML 11.00.9600.20139(NOTE)*
		<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"><HTML><HEAD><META content="text/html; charset=windows-1252" http-equiv=Content-Type><STYLE> BODY margin:0; P margin:0 </STYLE><META name=GENERATOR content="MSHTML 11.00.9600.20139(NOTE)*
		AGE > 9 years(NOTE)*
	baricitinib
		4 mg, Tab, By Mouth, DAILY, duration: 14 Dose(s)/Time(s)
			Comment: Not recommended for eGFR < 15ml/min, dose may be given as oral dispersion, G-tube or NG tube in patients if unable to swallow whole tablets.
		AGE 2-8 years(NOTE)*
		2 mg, Tab, By Mouth, DAILY, duration: 14 Dose(s)/Time(s)
			Comment: Not recommended for eGFR < 30ml/min, dose may be given as oral dispersion, G-tube or NG tube in patients if unable to swallow whole tablets.

*Report Legend:
DEF - This order sentence is the default for the selected order
GOAL - This component is a goal
IND - This component is an indicator
INT - This component is an intervention
IVS - This component is an IV Set
NOTE - This component is a note
Rx - This component is a prescription
SUB - This component is a sub phase